Cargando…
霉酚酸酯预防疗程对单倍体相合造血干细胞移植急性移植物抗宿主病的影响
OBJECTIVE: To investigate the impact of mycophenolate mofetil (MMF) prophylaxis duration on acute graft-versus-host disease (aGVHD) after haploidentical stem cell transplantation (haplo-HSCT) using ‘Beijing Protocol’. METHODS: Adult patients (≥14 years) received haplo-HSCT in Peking University Insti...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342124/ https://www.ncbi.nlm.nih.gov/pubmed/29779322 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.04.005 |
_version_ | 1783555373714636800 |
---|---|
collection | PubMed |
description | OBJECTIVE: To investigate the impact of mycophenolate mofetil (MMF) prophylaxis duration on acute graft-versus-host disease (aGVHD) after haploidentical stem cell transplantation (haplo-HSCT) using ‘Beijing Protocol’. METHODS: Adult patients (≥14 years) received haplo-HSCT in Peking University Institute of Hematology from Sep, 2016 to Mar, 2017 were retrospectively reviewed if they fulfilled the criterias: ①diagnosed with hematological maligancies; ②standard-risk status at haplo-HSCT. A total of 237 patients [including 102 patients with long MMF duration (defined as started on day −9 with 100 mg/d, adjusted to 500 mg/d from day +30 and discontinued on day +45 to +60 or occurrence of CMV/EBV reactivation or late-onset hemorrhagic cytitis), and 135 patients with short MMF duration (defined as started on day −9 with 500 mg/d and discontinued on the day achieved neutrophil engraftment)] were reviewed. The incidence of aGVHD, virus infection and overall survival (OS) were compared between the two groups. RESULTS: The median durations of MMF prophylaxis of long and short duration groups were 27(7–71) and 15(9–24) days, respectively after haplo-HSCT. There were no differences of baseline characteristics (including sex, patient age, disease, mismatched HLA loci, donor-recipient relation, donor-recipient sex and donor age) between the two groups. The incidences of the grade Ⅱ–Ⅳ and Ⅲ/Ⅳ aGVHD in long and short duration groups were 31.1% versus 17.6% (P=0.018) and 7.4% verus 7.8% (P=0.900), respectively. The duration of MMF prophylaxis was not found to be associated with gradeⅡ–Ⅳ aGVHD by the multivariate analysis. There were no significant differences in terms of CMV viremia, EBV viremia, hemorrhagic cytitis and OS between the two groups. CONCLUSION: Prophylaxis with short duration MMF in the setting of ‘Beijing protocol’ haplo-SCT was not associated with increased acute GVHD with no impact on OS, which indicated that short duration MMF might be a feasible GVHD prophylaxis regimen. |
format | Online Article Text |
id | pubmed-7342124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73421242020-07-16 霉酚酸酯预防疗程对单倍体相合造血干细胞移植急性移植物抗宿主病的影响 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the impact of mycophenolate mofetil (MMF) prophylaxis duration on acute graft-versus-host disease (aGVHD) after haploidentical stem cell transplantation (haplo-HSCT) using ‘Beijing Protocol’. METHODS: Adult patients (≥14 years) received haplo-HSCT in Peking University Institute of Hematology from Sep, 2016 to Mar, 2017 were retrospectively reviewed if they fulfilled the criterias: ①diagnosed with hematological maligancies; ②standard-risk status at haplo-HSCT. A total of 237 patients [including 102 patients with long MMF duration (defined as started on day −9 with 100 mg/d, adjusted to 500 mg/d from day +30 and discontinued on day +45 to +60 or occurrence of CMV/EBV reactivation or late-onset hemorrhagic cytitis), and 135 patients with short MMF duration (defined as started on day −9 with 500 mg/d and discontinued on the day achieved neutrophil engraftment)] were reviewed. The incidence of aGVHD, virus infection and overall survival (OS) were compared between the two groups. RESULTS: The median durations of MMF prophylaxis of long and short duration groups were 27(7–71) and 15(9–24) days, respectively after haplo-HSCT. There were no differences of baseline characteristics (including sex, patient age, disease, mismatched HLA loci, donor-recipient relation, donor-recipient sex and donor age) between the two groups. The incidences of the grade Ⅱ–Ⅳ and Ⅲ/Ⅳ aGVHD in long and short duration groups were 31.1% versus 17.6% (P=0.018) and 7.4% verus 7.8% (P=0.900), respectively. The duration of MMF prophylaxis was not found to be associated with gradeⅡ–Ⅳ aGVHD by the multivariate analysis. There were no significant differences in terms of CMV viremia, EBV viremia, hemorrhagic cytitis and OS between the two groups. CONCLUSION: Prophylaxis with short duration MMF in the setting of ‘Beijing protocol’ haplo-SCT was not associated with increased acute GVHD with no impact on OS, which indicated that short duration MMF might be a feasible GVHD prophylaxis regimen. Editorial office of Chinese Journal of Hematology 2018-04 /pmc/articles/PMC7342124/ /pubmed/29779322 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.04.005 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 霉酚酸酯预防疗程对单倍体相合造血干细胞移植急性移植物抗宿主病的影响 |
title | 霉酚酸酯预防疗程对单倍体相合造血干细胞移植急性移植物抗宿主病的影响 |
title_full | 霉酚酸酯预防疗程对单倍体相合造血干细胞移植急性移植物抗宿主病的影响 |
title_fullStr | 霉酚酸酯预防疗程对单倍体相合造血干细胞移植急性移植物抗宿主病的影响 |
title_full_unstemmed | 霉酚酸酯预防疗程对单倍体相合造血干细胞移植急性移植物抗宿主病的影响 |
title_short | 霉酚酸酯预防疗程对单倍体相合造血干细胞移植急性移植物抗宿主病的影响 |
title_sort | 霉酚酸酯预防疗程对单倍体相合造血干细胞移植急性移植物抗宿主病的影响 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342124/ https://www.ncbi.nlm.nih.gov/pubmed/29779322 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.04.005 |
work_keys_str_mv | AT méifēnsuānzhǐyùfángliáochéngduìdānbèitǐxiānghézàoxuègànxìbāoyízhíjíxìngyízhíwùkàngsùzhǔbìngdeyǐngxiǎng AT méifēnsuānzhǐyùfángliáochéngduìdānbèitǐxiānghézàoxuègànxìbāoyízhíjíxìngyízhíwùkàngsùzhǔbìngdeyǐngxiǎng AT méifēnsuānzhǐyùfángliáochéngduìdānbèitǐxiānghézàoxuègànxìbāoyízhíjíxìngyízhíwùkàngsùzhǔbìngdeyǐngxiǎng AT méifēnsuānzhǐyùfángliáochéngduìdānbèitǐxiānghézàoxuègànxìbāoyízhíjíxìngyízhíwùkàngsùzhǔbìngdeyǐngxiǎng AT méifēnsuānzhǐyùfángliáochéngduìdānbèitǐxiānghézàoxuègànxìbāoyízhíjíxìngyízhíwùkàngsùzhǔbìngdeyǐngxiǎng AT méifēnsuānzhǐyùfángliáochéngduìdānbèitǐxiānghézàoxuègànxìbāoyízhíjíxìngyízhíwùkàngsùzhǔbìngdeyǐngxiǎng AT méifēnsuānzhǐyùfángliáochéngduìdānbèitǐxiānghézàoxuègànxìbāoyízhíjíxìngyízhíwùkàngsùzhǔbìngdeyǐngxiǎng |